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The porphyrias are a group of eight metabolic disorders, 
each of which is associated with a specific enzymatic 
alteration in the haem biosynthetic pathway.[1] In 
general, the porphyrias share one or both of two clinical 
symptom complexes: cutaneous photosensitivity, 
which results from the interaction of light and photoactive porphyrin 
molecules in the skin; and the acute attack, a serious complication 
associated with a phase of accelerated hepatic porphyrin synthesis. 
The acute attack is a feature of four porphyrias: acute intermittent 
porphyria (AIP); variegate porphyria; hereditary coproporphyria; 
and aminolaevulinic acid (ALA) dehydratase porphyria. All four are 
so-called ‘hepatic’ porphyrias, in which the haem synthetic defect is 
expressed in non-erythroid cells, notably hepatocytes.
The acute attack is a potentially severe illness that may result in 
severe debilitation and death. The clinical features are metabolic, 
principally hyponatraemia, and neurological, related to autonomic, 
motor and cerebral dysfunction.[2-4] Autonomic dysfunction is 
associated with a characteristic diffuse, severe and poorly localised 
abdominal pain, sympathetic over-activity manifesting as tachycardia, 
hypertension or a labile blood pressure and cardiac arrhythmias, and 
gastrointestinal dysfunction causing nausea, vomiting and ileus. 
Cerebral dysfunction may present as seizures, transient cerebral 
ischaemia, posterior reversible encephalopathy syndrome (PRES) 
or coma.[5] Seizures may be precipitated by hyponatraemia, cerebral 
ischaemia and the administration of epileptogenic medication, such 
as pethidine (meperidine) prescribed for pain relief.[6] Hyponatraemia 
may result from the syndrome of inappropriate antidiuretic hormone 
secretion (SIADH), renal tubular dysfunction and the administration 
of hypotonic intravenous fluids such as dextrose.[7] Rarely, brainstem 
dysfunction may occur in response to transient ischaemia or 
hyponatraemia,[8] as may cerebral infarction.[9] Acute psychotic states 
are occasionally observed.[10] All these alarming features, other than 
the pain, nausea and cardiovascular effects, are seen in a minority 
of cases, and usually accompany a particularly severe and often 
unrecognised, untreated acute attack.
A more common manifestation of more severe attacks is a sudden-onset, 
predominantly motor, peripheral neuropathy. The typical presentation is 
of a rapid onset of muscle weakness following a prodrome of 1 - 2 days 
of abdominal pain and other symptoms of the acute attack. Sensory 
symptoms are never prominent. Muscle weakness is symmetrical and 
evenly distributed in the proximal and distal muscle groups of the upper 
limbs, although it may typically start proximally, particularly in the legs. [11] 
In our experience, it is not infrequently misdiagnosed as Guillain-Barré 
syndrome. Progressive weakness can progress to respiratory failure. 
Cranial nerve involvement may occur. Before the introduction of modern 
techniques of assisted ventilation, such attacks were fatal. Quadriparesis 
is reversible, but may require prolonged ventilatory support and many 
months of rehabilitation. Occasionally patients present with atypical 
neurological manifestations. Single cases of mononeuritis multiplex[12] 
and ‘pseudomyasthenia’ during an acute attack have been described. 
Patients with pre-existing neuropathy who experience recurrent attacks 
may demonstrate a transient decrease in muscle strength with a return to 
baseline following cessation of the attack.[13]
Nerve conduction studies and pathological examination typically 
indicate a pattern of axonal necrosis rather than demyelination.[3] The 
pathogenesis is poorly understood. A direct, toxic effect of the porphyrin 
precursors, particularly ALA, on neuronal tissue has been postulated. 
Interestingly, the chemical structure of ALA closely resembles that 
of γ-aminobutyric acid (GABA), a known neurotransmitter.[13] A 
contrasting hypothesis is that porphyria-associated impaired haem 
synthesis results in intraneuronal haem deficiency, with consequent 
intracellular energy depletion and dysfunction.[14] This view has become 
less tenable since repeated experience with liver transplantation has 
shown that this effectively removes the potential for future acute attacks 
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in patients subject to frequent and debilitating recurrent attacks,[15] even 
though haem biosynthesis in all non-erythroid cells, including neurons 
(with the exception of the engrafted hepatocytes), continue to operate 
in a haem-deficient environment.
The symptomatic patient with an acute, severe porphyria therefore 
typically presents with a sudden onset of a characteristic syndrome 
of acute abdominal pain, accompanied by other clinical features 
as described above, which may then progress to a sudden onset of 
quadriparesis over the course of a few hours. Recovery thereafter may 
be prolonged. The unfortunate patient may have further acute attacks 
following the same pattern.
In this issue of the SAMJ, an atypical neurological presentation of 
AIP in a young man is described.[16] Two points are of particular interest. 
Firstly, although the observed pattern of neurological dysfunction was 
quite compatible with an acute porphyria, the expected history of 
an abrupt onset preceded by a short prodrome of typical porphyric 
symptoms was completely absent. There were no preceding symptoms 
suggestive of an acute attack, and weakness developed cumulatively 
over a prolonged period. It is not surprising that a condition such as 
motor neuron disease featured prominently in the initial differential 
diagnosis. The patient was fortunate in that, certain inconsistent 
features having been recognised, he was referred to a neurology unit 
where exclusion of porphyria is a standard practice for patients with 
unexplained neuropathy, given the very high prevalence of porphyria 
in the South African population.[17] The second point of interest is the 
rapid improvement in neurological function in response to definitive 
therapy for porphyria with haem arginate. Given that the predominant 
underlying pathological state is one of severe axonal necrosis, rapid 
improvement is not expected. Yet, in this case treatment was followed 
by a prompt, though partial, improvement. That it was incomplete 
is easily explained given that neurophysiological studies did indeed 
confirm the presence of axonal necrosis. It does, however, support 
the suggestion that, in at least some cases, motor neuron function is 
transiently depressed under circumstances of haem depletion, with the 
potential for rapid improvement when this is corrected.[6]
Two conclusions may be drawn from this report. For the clinician it 
is a reminder that acute forms of porphyria should never be forgotten 
when confronted with a patient with unexplained motor neuropathy, 
whether or not the characteristic features of the acute attack are 
present. For those with a research interest in neuropathophysiology, 
it is an invitation: an interesting, fruitful and under-explored field 
– the interplay of disordered haem synthesis and neuronal function – 
awaits detailed study and definitive answers.
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